AbbVie Inc.
Pharmacyclics Inc.

North Chicago, Illinois-based biopharmaceutical company AbbVie Inc. said March 4 it will buy Sunnyvale, California-based Pharmacyclics, which specializes in cancer treatment, for $21 billion.

AbbVie is being represented by a team from Wachtell, Lipton, Rosen & Katz led by corporate partners Edward Herlihy, David Karp and David Lam. The team also includes antitrust partner Joseph Larson, executive compensation and benefits partner David Kahan, finance partners Joshua Feltman and Gregory Pessin and tax partner Joshua Holmes. Associates working on the deal include Michael Benn, Jeffrey Lee, Jenna Levine, Kate Napalkova, S. Iliana Ongun, Elina Tetelbaum, Lauren Thomas and Alisha Turak.

Wilson Sonsini Goodrich & Rosati is representing Pharmacyclics with a team that includes mergers and acquisitions partners Robert Ishii and Denny Kwon; IP technology transactions partner Miranda Biven and IP counseling and patents partner Michael Hostetler; employee benefits and compensation partner Scott McCall; tax partner Ivan Humphreys; and antitrust partner Scott Sher and associate Derek Liu.